TrialBlood cancer journal2019

Addition of cyclophosphamide on insufficient response to pomalidomide and dexamethasone: results of the phase II PERSPECTIVE Multiple Myeloma trial.

Katja C Weisel et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.